Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Generation Bio Co

Current price
2.73 USD -0.07 USD (-2.50%)
Last closed 2.8 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 143 702 208 USD
Yield for 12 month -46.26 %
21.11.2021 - 28.11.2021

Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. Address: 301 Binney Street, Cambridge, MA, United States, 02142

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price

7.5 USD

P/E ratio

Dividend Yield

Current Year

+5 904 000 USD

Last Year

+880 000 USD

Current Quarter

+4 059 000 USD

Last Quarter

+2 878 000 USD

Current Year

+641 000 USD

Last Year

-5 130 000 USD

Current Quarter

+2 747 000 USD

Last Quarter

+912 000 USD

Key Figures GBIO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -119 156 000 USD
Operating Margin TTM -510.08 %
PE Ratio
Return On Assets TTM -21.68 %
PEG Ratio
Return On Equity TTM -82.24 %
Wall Street Target Price 7.5 USD
Revenue TTM 9 963 000 USD
Book Value 1.99 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings per share -2.55 USD
Diluted Eps TTM -2.55 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics GBIO

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History GBIO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation GBIO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 13.4647
Price Sales TTM 41.6608
Enterprise Value EBITDA -0.5964
Price Book MRQ 1.2109

Financials GBIO

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators GBIO

For 52 weeks

0.86 USD 6.98 USD
50 Day MA 3.05 USD
Shares Short Prior Month 1 536 784
200 Day MA 2.51 USD
Short Ratio 11.19
Shares Short 1 515 690
Short Percent 3.82 %

Dynamics of changes in the value of assets



2.24 EUR CITIZENS INC. A -0.04 (-1.75%)
Detailed analytics


11.14 USD Blockchain Coinvestors Acquisition Corp I -0.01 (-0.09%)
Detailed analytics


0.19 USD US Masters Residential Property Fund 0 (0%)
Detailed analytics


2.47 USD Genesis Land Development Corp 0 (0%)
Detailed analytics


793.00 JPY IKK Inc +0.03 (+0.63%)
Detailed analytics